RAM
EWTX icon

Riggs Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

Riggs Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-49
Closed -$643 – 363
2025
Q2 		$643 Buy
+49
New +$707 ﹤0.01% 818

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Riggs Asset Management's EWTX Position: Q3 2025 in Review

Riggs Asset Management sold out of Edgewise Therapeutics (EWTX) in Q3 2025, closing a stake of 49 shares — an estimated $643 sold.

Riggs Asset Management first reported a position in EWTX in Q2 2025 and held it in 1 quarter. The position peaked at $643 in Q2 2025. 173 funds tracked by Wall St. Rank hold EWTX as of Q3 2025.

  • Riggs Asset Management reported no remaining Edgewise Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Riggs Asset Management sold 49 Edgewise Therapeutics shares in Q3 2025, an estimated $643.
  • Riggs Asset Management first reported a position in Edgewise Therapeutics in Q2 2025 and held it in 1 quarter.
  • Riggs Asset Management's Edgewise Therapeutics position peaked at $643 in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2025.

Based on Riggs Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.